1EBA image
Deposition Date 1998-10-02
Release Date 1998-11-11
Last Version Date 2024-10-30
Entry Detail
PDB ID:
1EBA
Title:
COMPLEX BETWEEN THE EXTRACELLULAR DOMAIN OF ERYTHROPOIETIN (EPO) RECEPTOR [EBP] AND AN INACTIVE PEPTIDE [EMP33] CONTAINS 3,5-DIBROMOTYROSINE IN POSITION 4 (DENOTED DBY)
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.70 Å
R-Value Free:
0.29
R-Value Work:
0.2
R-Value Observed:
0.2
Space Group:
P 2 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:PROTEIN (ERYTHROPOIETIN RECEPTOR)
Gene (Uniprot):EPOR
Chain IDs:A, B
Chain Length:215
Number of Molecules:2
Biological Source:Homo sapiens
Modified Residue
Compound ID Chain ID Parent Comp ID Details 2D Image
DBY C TYR 3,5 DIBROMOTYROSINE
Ligand Molecules
Primary Citation
An antagonist peptide-EPO receptor complex suggests that receptor dimerization is not sufficient for activation.
Nat.Struct.Biol. 5 993 1004 (1998)
PMID: 9808045 DOI: 10.1038/2965

Abstact

Dimerization of the erythropoietin (EPO) receptor (EPOR), in the presence of either natural (EPO) or synthetic (EPO-mimetic peptides, EMPs) ligands is the principal extracellular event that leads to receptor activation. The crystal structure of the extracellular domain of EPOR bound to an inactive (antagonist) peptide at 2.7 A resolution has unexpectedly revealed that dimerization still occurs, but the orientation between receptor molecules is altered relative to active (agonist) peptide complexes. Comparison of the biological properties of agonist and antagonist EMPs with EPO suggests that the extracellular domain orientation is tightly coupled to the cytoplasmic signaling events and, hence, provides valuable new insights into the design of synthetic ligands for EPOR and other cytokine receptors.

Legend

Protein

Chemical

Disease

Primary Citation of related structures